2017
DOI: 10.1152/ajpcell.00097.2017
|View full text |Cite
|
Sign up to set email alerts
|

Reduced SCD1 activity alters markers of fatty acid reesterification, glyceroneogenesis, and lipolysis in murine white adipose tissue and 3T3-L1 adipocytes

Abstract: White adipose tissue (WAT) has a critical role in lipid handling. Previous work demonstrated that SCD1 is an important regulator of WAT fatty acid (FA) composition; however, its influence on the various interconnected pathways influencing WAT lipid handling remains unclear. Our objective was to investigate the role of SCD1 on WAT lipid handling using knockout (KO) mice and SCD1-inhibited 3T3-L1 adipocytes by measuring gene, protein, and metabolite markers related to FA reesterification, glyceroneogenesis, and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
17
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(17 citation statements)
references
References 34 publications
0
17
0
Order By: Relevance
“…The role of SCD1 is still controversial. SCD1 deficiency reduced lipogenesis and improved insulin sensitivity in adipose tissue ( Flowers and Ntambi, 2008 ; Ralston and Mutch, 2015 ); however, SCD1-deficient mice have altered fatty acid re-esterification and glyceroneogenesis in white adipose tissue ( Dragos et al, 2017 ). In Sq- and HH-Sq-treated cells, SCD1 gene expression was increased but did not show any aberrant lipid accumulation in adipocytes.…”
Section: Discussionmentioning
confidence: 99%
“…The role of SCD1 is still controversial. SCD1 deficiency reduced lipogenesis and improved insulin sensitivity in adipose tissue ( Flowers and Ntambi, 2008 ; Ralston and Mutch, 2015 ); however, SCD1-deficient mice have altered fatty acid re-esterification and glyceroneogenesis in white adipose tissue ( Dragos et al, 2017 ). In Sq- and HH-Sq-treated cells, SCD1 gene expression was increased but did not show any aberrant lipid accumulation in adipocytes.…”
Section: Discussionmentioning
confidence: 99%
“…Pck1 encodes the gluconeogenic enzyme PCK1, but in WAT, this enzyme is more glyceroneogenic [41]. SCD1 catalytically de-saturates fatty acyl–CoA substrates and also plays a role in glyceroneogenesis [42]. Targeted deletion of Scd1 in adipocytes impaired glyceroneogenesis in WAT, concomitant with the reduced other glyceroneogenesis markers, including the downregulation of Pck1 [42].…”
Section: Discussionmentioning
confidence: 99%
“…SCD1 catalytically de-saturates fatty acyl–CoA substrates and also plays a role in glyceroneogenesis [42]. Targeted deletion of Scd1 in adipocytes impaired glyceroneogenesis in WAT, concomitant with the reduced other glyceroneogenesis markers, including the downregulation of Pck1 [42]. Dysregulation of glyceroneogenesis in WAT induced by Pck1 mutation resulted in elevated TG levels in liver [43], impaired WAT glucose uptake and global glucose intolerance [43], a similar metabolic phenotype as seen in high dose NR-treated mice in our study.…”
Section: Discussionmentioning
confidence: 99%
“…The rate of appearance of free fatty acids in the plasma is a function of the balance between lipolysis and reesterification in the adipose tissue [32]. Increased lipolysis and reduced reesterification have been observed in SCD1 knockout mice and after SCD1 inhibition in 3T3-L1 adipocytes [33]. Conversely, rosiglitazone treatment is known to increase SCD1 activity, reduce free fatty acid turnover, and improve peripheral insulin sensitivity, possibly by reducing fatty acid trafficking in the muscle [34,35].…”
Section: Discussionmentioning
confidence: 99%